Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on May 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
- Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
- Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
- Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.
BridgeBio Pharma Price Performance
BBIO opened at $67.40 on Thursday. BridgeBio Pharma, Inc. has a 12 month low of $38.57 and a 12 month high of $84.94. The stock has a market capitalization of $13.20 billion, a price-to-earnings ratio of -18.02 and a beta of 0.97. The business has a fifty day moving average price of $70.51 and a 200 day moving average price of $72.15.
Wall Street Analysts Forecast Growth
Several research firms recently commented on BBIO. HC Wainwright reissued a “buy” rating and set a $110.00 target price on shares of BridgeBio Pharma in a research note on Thursday, May 28th. Barclays reissued an “overweight” rating on shares of BridgeBio Pharma in a research note on Tuesday, March 10th. Oppenheimer lowered their target price on BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. Leerink Partners reissued an “outperform” rating and set a $98.00 target price on shares of BridgeBio Pharma in a research note on Thursday, March 12th. Finally, Canaccord Genuity Group began coverage on BridgeBio Pharma in a research report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 price objective for the company. Twenty-three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average target price of $89.59.
Insider Transactions at BridgeBio Pharma
In related news, CFO Thomas Trimarchi sold 13,651 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $65.08, for a total value of $888,407.08. Following the completion of the sale, the chief financial officer directly owned 359,194 shares of the company’s stock, valued at $23,376,345.52. This represents a 3.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $71.58, for a total value of $143,160.00. Following the completion of the sale, the chief accounting officer directly owned 134,115 shares of the company’s stock, valued at approximately $9,599,951.70. This trade represents a 1.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 171,754 shares of company stock valued at $11,914,859 in the last 90 days. Company insiders own 14.23% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at about $31,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at about $34,000. Jones Financial Companies Lllp acquired a new stake in shares of BridgeBio Pharma in the 1st quarter valued at about $35,000. Huntington National Bank boosted its position in shares of BridgeBio Pharma by 111.7% in the 3rd quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after purchasing an additional 392 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares during the period. 99.85% of the stock is owned by institutional investors and hedge funds.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About BridgeBio Pharma
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Recommended Stories
- Five stocks we like better than BridgeBio Pharma
- The “Duck Stock” Keeps Quietly Making Money for Shareholders
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
